还原型谷胱甘肽联合熊去氧胆酸治疗非酒精性脂肪性肝病疗效评价  

Glutathione Combined with Ursodeoxycholic Acid in Treating Non-Alcoholic Fatty Liver Disease

作　　者：徐卫明[1] 

机构地区：[1]上海交通大学附属第六人民医院南院急诊科,上海201400

出　　处：《中国药业》2016年第15期51-53,共3页China Pharmaceuticals

摘　　要：目的观察还原型谷胱甘肽联合熊去氧胆酸治疗非酒精性脂肪性肝病（NAFLD）的临床疗效。方法选取2013年9月至2015年8月收治的74例NAFLD患者，按照随机数字表法分为对照组和治疗组，各37例。对照组采用还原型谷胱甘肽治疗，治疗组在此基础上联合熊去氧胆酸治疗，对比两组治疗效果。结果治疗组总有效率为95．59％，优于对照组的67．57％（χ^2=7．1357，P〈0．05）。两组治疗前各项肝功能指标差异不明显（P〉0．05），治疗后治疗组各项肝功能改善情况显著优于对照组（P〈0．05）。治疗组各项实验室指标水平同对照组比较，均明显较低，差异存在统计学意义（P〈0．05）。结论还原型谷胱甘肽联合熊去氧胆酸治疗NAFLD临床疗效确切，可显著改善患者肝功能，值得临床选择和普及。Objective To investigate the clinical efficacy of reduced glutathione combined with ursodeoxycholic acid in the treatment of non- alcoholic fatty liver disease（NAFLD）. Methods 74 patients with NAFLD from September 2013 and August 2015 were divided into control group and treatment group according to the random number table method, 37 cases in each group. The control was treated with reduced glutathione, and the treatment group was added with ursodeoxycholic acid on the basis of the control group. The clinical effieacies of the two groups were compared. Results The total effective rate of the treatment group was 95.59%, which was better than 67.57% of the control group, the difference was statistically significant（χ^2 =7. 135 7, P 〈 0.05）; the liver function indexes of the two groups before treatment were not obvious（ P 〉 0.05）, after treatment, the liver function of treatment group improves better than that of the reference group（ P 〈 0. 05）. The BMI, DBP, TG, TC, UA, FBG level of patients in the treatment group were significantly lower than that of reference group with statistically significance（ P 〈 0. 05）. Conclusion Reduced glutathione combined with ursodeoxycholic acid treatment of nonalcoholic fatty liver has clinical curative effect, can significantly improve the liver function of patients, worthy of clinical choice and popularization.

关 键 词：熊去氧胆酸 非酒精性脂肪肝 还原型谷胱甘肽 临床疗效 肝功能 

分 类 号：R969.4[医药卫生—药理学] R975.5[医药卫生—药学]